By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Astellas Pharma Inc. 

3-11 Nihonbashi-Honcho 2-chome

Chuo-ku  Tokyo  103-8411  Japan
Phone: 81-3-3244-3000 Fax: 81-3-3244-3272





Gilead (Durham, NC) 

Company News
Astellas (ALPMY) Release: FDA Approves Supplemental New Drug Application For XTANDI (Enzalutamide) Capsules In Advanced Prostate Cancer 10/21/2016 10:52:26 AM
World Anti-Doping Agency And Astellas (ALPMY) Announce Global Initiative To Prevent Misuse And Abuse Of Medicines For Doping In Sports 10/14/2016 11:57:40 AM
Chromocell And Astellas (ALPMY) Announce FDA Fast Track Designation And First Subject Dosing With Lead Candidate CC8464/ASP1807 For The Management Of Neuropathic Pain Associated With iSFN 10/13/2016 6:48:44 AM
Seattle Genetics (SGEN) And Agensys, Inc., An Affiliate Of Astellas (ALPMY), Highlight Promising Enfortumab Vedotin (ASG-22ME) And ASG-15ME Phase 1 Data In Metastatic Urothelial Cancer At 2016 ESMO Congress 10/7/2016 11:00:51 AM
Astellas (ALPMY) Expands Leadership In Oncology Clinical Development 10/5/2016 9:17:15 AM
Cytokinetics (CYTK) Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Expanded Collaboration With Astellas (ALPMY) 9/29/2016 7:43:28 AM
Working Mother Magazine Names Astellas (ALPMY) Among 100 Best Companies in the US Across All Industries 9/28/2016 11:11:30 AM
Astellas (ALPMY), Vical  (VICL)'s Experimental Herpes Vaccine Flunks Mid-Stage Test 9/19/2016 5:43:21 AM
Courtagen Collaborates With Astellas (ALPMY) For Mitochondrial Disorder Drug Development 9/15/2016 10:41:55 AM
Astellas (ALPMY) And World Transplant Games Federation Announce Launch Of Fit For Life! To Promote Physical Activity In Transplant Recipients Worldwide 8/19/2016 8:10:12 AM